Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA | Authors

Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA, on Key Highlights of the Phase 3 ASPEN Trial

July 16, 2020

The trial evaluated zanubrutinib, a potent and selective BTK inhibitor, versus ibrutinib, a first generation BTK inhibitor, in patients with Waldenström macroglobulinemia.

Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA, on the Phase 3 ASPEN Trial

June 23, 2020

Results from the trial indicated that zanubrutinib was associated with a higher complete response or very good partial response rate and demonstrated clinically meaningful advances in safety and tolerability in patients with Waldenström macroglobulinemia.

Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA, on Results of the Phase III ASPEN Trial

June 08, 2020

The trial compared zanubrutinib, a potent and selective BTK inhibitor, versus ibrutinib, a first generation BTK inhibitor, in patients with Waldenström macroglobulinemia.